详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

A Interim Analysis of Randomized Phase III Trial of Nedaplatin or Cisplatin Combined with Docetaxel as First-Line Treatment for Advanced ASQC

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Shanghai Jiao Tong Univ, Shanghai Lung Canc Ctr, Shanghai Chest Hosp, Shanghai 200030, Peoples R China [2]Cent S Univ, Xiangya Hosp, Dept Resp Med, Changsha, Hunan, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan 430074, Peoples R China [4]Shanghai Chest Hosp, Lung Canc Ctr, Shanghai, Peoples R China [5]Xijing Hosp, Xian, Peoples R China [6]Nanjing Mil Gen Hosp, Nanjing, Jiangsu, Peoples R China [7]Henan Canc Hosp, Zhengzhou, Peoples R China [8]Canc Hosp Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China [9]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan 430074, Peoples R China [10]Guangxi Med Univ, Canc Hosp, Med Oncol, Nanning, Peoples R China [11]First Hosp Zhejiang Prov, Med Oncol, Hangzhou, Zhejiang, Peoples R China [12]Beijing Canc Hosp, Med Oncol, Beijing, Peoples R China [13]Capital Med Univ, Beijing Chest Hosp, Oncol, Beijing, Peoples R China

出处：

ISSN：

关键词： squamous cell carcinoma chemotherapy

语种：

WOS：

中科院(CAS)分区：

出版当年[2014]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2013]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 5.8 出版当年[2013版] 4.948 出版当年五年平均 4.473 出版前一年[2012版] 5.282 出版后一年[2014版]

第一作者：

第一作者单位： [1]Shanghai Jiao Tong Univ, Shanghai Lung Canc Ctr, Shanghai Chest Hosp, Shanghai 200030, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma [2]Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma [3]Salicylate sensitizes oral squamous cell carcinoma to chemotherapy through targeting mTOR pathway [4]Oncolytic viro-chemotherapy exhibits antitumor effect in laryngeal squamous cell carcinoma cells and mouse xenografts [5]Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial [6]CSMD1 suppresses cancer progression by inhibiting proliferation, epithelial-mesenchymal transition, chemotherapy-resistance and inducing immunosuppression in esophageal squamous cell carcinoma [7]Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung [8]Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia [9]Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study [10]Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.